Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets.

INTRODUCTION Pancreatic A- and B-cells express somatostatin receptors (SSTRs). Five pharmacologically distinct SSTR subtypes are known (SSTR1-SSTR5). In rodents, SSTR2 inhibits glucagon secretion, whereas SSTR5 suppresses the release of insulin. Human pancreatic A- and B-cells express SSTR1-3 and SSTR5; however, their contribution to the regulation of glucagon and insulin secretion is not well known. AIM OF THE STUDY The goal of this study was to characterize the role of individual SSTR subtypes in regulating human glucagon and insulin secretion in vitro. METHODS Human pancreatic islets were isolated from healthy donors and incubated with somatostatin, SSTR1-3-selective and SSTR5-selective agonists, or an SSTR2-selective antagonist (DC-41-33). Stimulation of insulin secretion was induced by glucose (10, 20 mm) alone or in combination with 10 nm exendin-4 or 10 mm L-arginine. Glucagon secretion was induced by 20 mm L-arginine. Basal secretion of insulin and glucagon was measured at 2.8 or 3.3 mm glucose. RESULTS SSTR1-, SSTR2-, and SSTR5-selective agonists inhibited insulin secretion with the following order of potency: SSTR2 (EC50, 0.08 nm) > SSTR5 (EC50, 5.3 nm) > SSTR1 (EC50, 35 nm). Glucagon secretion was inhibited by SSTR-selective agonists with the following order of potency: SSTR2 (EC50, 0.05 nm) > SSTR1 (EC50, 1.8 nm) > SSTR5 (EC50, 28 nm). DC-41-33 dose-dependently reversed the effects of the SSTR2-selective agonist on insulin and glucagon secretion. CONCLUSION Our study demonstrates that SSTR2-agonist is the most potent inhibitor of insulin and glucagon secretion from isolated human pancreatic islets. Furthermore, we identify SSTR1- and SSTR5-selective agonists as additional inhibitors of insulin and glucagon secretion from human pancreas.

[1]  T. Adrian,et al.  Intraislet somatostatin inhibits insulin (via a subtype-2 somatostatin receptor) but not islet amyloid polypeptide secretion in the isolated perfused human pancreas , 1997, Journal of Gastrointestinal Surgery.

[2]  Georg Breier,et al.  Vascular Endothelial Growth Factor Increases Functional β-Cell Mass by Improvement of Angiogenesis of Isolated Human and Murine Pancreatic Islets , 2005, Transplantation.

[3]  M. Brendel,et al.  INFLUENCE OF NEUTRAL PROTEASE ACTIVITY ON HUMAN ISLET ISOLATION OUTCOME , 2004, Transplantation proceedings.

[4]  F. Brunicardi,et al.  Double-gene ablation of SSTR1 and SSTR5 results in hyperinsulinemia and improved glucose tolerance in mice. , 2004, Surgery.

[5]  M. Stridsberg,et al.  Expression and Distribution of Somatostatin Receptor Subtypes in the Pancreatic Islets of Mice and Rats , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[6]  H. Noushmehr,et al.  Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. , 2003, Endocrinology.

[7]  T. Adrian,et al.  Activation of Somatostatin Receptor Subtype 2 Inhibits Insulin Secretion in the Isolated Perfused Human Pancreas , 2003, Pancreas.

[8]  D. Coy,et al.  Intra-islet somatostatin regulates glucagon release via type 2 somatostatin receptors in rats. , 2003, Diabetes.

[9]  H. Wilkinson,et al.  Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. , 2003, Molecular endocrinology.

[10]  H. Wilkinson,et al.  Somatostatin Receptor Subtypes 2 and 5 Inhibit Corticotropin-Releasing Hormone-Stimulated Adrenocorticotropin Secretion from AtT-20 Cells , 2002, Neuroendocrinology.

[11]  B. Portha,et al.  Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. , 2002, Diabetes.

[12]  D. Cocchi,et al.  Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. , 2002, Endocrinology.

[13]  A. Blake.  Somatostatin receptor subtype 1 (sst1) regulates intracellular 3′,5′-cyclic adenosine monophosphate accumulation in rat embryonic cortical neurons: evidence with L-797,591, an sst1-subtype-selective nonpeptidyl agonist , 2001, Neuropharmacology.

[14]  J. Schaeffer,et al.  Identification and characterization of subtype selective somatostatin receptor agonists , 2000, Journal of Physiology-Paris.

[15]  J. Schaeffer,et al.  Somatostatin Inhibits Insulin and Glucagon Secretion via Two Receptor Subtypes: An in Vitro Study of Pancreatic Islets from Somatostatin Receptor 2 Knockout Mice. , 2000, Endocrinology.

[16]  É. Mezey,et al.  Colocalization of Somatostatin Receptor sst5 and Insulin in Rat Pancreatic β-Cells. , 1999, Endocrinology.

[17]  Y. Patel.  Somatostatin and Its Receptor Family , 1999, Frontiers in Neuroendocrinology.

[18]  D. Pipeleers,et al.  Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. , 1999, Biochemical pharmacology.

[19]  J. Taylor,et al.  Highly potent cyclic disulfide antagonists of somatostatin. , 1999, Journal of medicinal chemistry.

[20]  M. Thangaraju,et al.  Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. , 1999, Diabetes.

[21]  R G Smith,et al.  Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. , 1998, Science.

[22]  J. Laissue,et al.  Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets. , 1998, The Journal of clinical endocrinology and metabolism.

[23]  B. Hering,et al.  Assessment of intracellular insulin content during all steps of human islet isolation procedure. , 1998, Cell transplantation.

[24]  B H Arison,et al.  Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  É. Mezey,et al.  Immunohistochemical Localization of Somatostatin Receptor SST2A in the Rat Pancreas. , 1997, Endocrinology.

[26]  É. Mezey,et al.  Erratum: Immunohistochemical localization of somatostatin receptor sst2A in the rat pancreas (Endocrinology (1997) 138 (2632-2635)) , 1997 .

[27]  H. Niznik,et al.  The somatostatin receptor family. , 1995, Life sciences.

[28]  T. Adrian,et al.  Somatostatin inhibits B-cell secretion via a subtype-2 somatostatin receptor in the isolated perfused human pancreas. , 1995, The Journal of surgical research.

[29]  C. B. Srikant,et al.  Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). , 1994, Endocrinology.

[30]  D. Coy,et al.  Specific inhibition of rat pancreatic insulin or glucagon release by receptor-selective somatostatin analogs. , 1994, Biochemical and biophysical research communications.

[31]  G. Taborsky,et al.  Pancreatic Somatostatin is a Mediator of Glucagon Inhibition by Hyperglycemia , 1987, Diabetes.

[32]  N. Ling,et al.  Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone , 1973, Science.